Therapeutic Advances in Chronic Disease is a distinguished open-access journal published by SAGE Publications Ltd, with a focus on innovative research and clinical practices addressing chronic diseases—a field increasingly relevant in today's healthcare landscape. Since its inception in 2010, the journal has committed itself to disseminating high-quality research that informs both theory and practice. With an impressive impact factor and ranked Q1 in Medicine (miscellaneous) in 2023, this journal boasts recognition as one of the top-tier publications in the medical community, placing it in the 79th percentile among its peers. Accessible since 2019, it aims to bridge the gap between cutting-edge research and its application in improving patient outcomes, inviting contributions from researchers, clinicians, and health professionals. The journal's comprehensive scope encompasses various aspects of chronic disease management, making it an invaluable resource for those seeking to advance their understanding of this critical field.

The JOURNAL OF CLINICAL PSYCHIATRY is a premier publication dedicated to advancing the understanding and treatment of psychiatric disorders. Established in 1978 and published by Physicians Postgraduate Press, this esteemed journal provides a vital platform for researchers, clinicians, and mental health professionals to share innovative findings and evidence-based practices in psychiatry. With an impressive impact factor and recognized as a Q1 journal in both Medicine (miscellaneous) and Psychiatry and Mental Health, the journal ranks among the top in its field, sitting at 96th out of 567 in Scopus rankings, placing it in the 83rd percentile. The journal's commitment to high-quality, peer-reviewed articles facilitates the dissemination of knowledge crucial for advancing clinical practices and improving patient outcomes. Access to its latest research is offered through institutional subscriptions, making it an essential resource for anyone involved in the mental health sector, from seasoned practitioners to aspiring students.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE is a pivotal journal in the fields of neurology, psychiatry, and related medical disciplines, published by GEORG THIEME VERLAG KG in Germany. With a history dating back to 1955, this journal has evolved to address the dynamic nature of neurological and psychiatric research, offering valuable insights and advancements in the field. Despite holding a Q4 category status in various medical domains according to the 2023 quartiles, the journal continues to foster academic discussion and engagement among researchers and clinicians alike. It serves as a vital platform for disseminating knowledge through original research articles, reviews, and clinical studies, making it an essential resource for professionals and students aiming to stay abreast of the latest developments in mental health and neurological science. Although the journal currently does not offer open access options, its contribution to the academic community is significant, helping to illuminate the intricate relationships between neurological disorders and psychiatric conditions.

Contemporary Clinical Trials Communications, published by ELSEVIER INC, serves as a pivotal resource in the evolving fields of medicine and pharmacology, especially with its commitment to open access since 2015. With the E-ISSN 2451-8654, this journal is dedicated to disseminating high-quality research that examines contemporary clinical trial methodologies and their applications in improving healthcare outcomes. Situated in the United States, its impressive ranking, with a Q2 status in both Medicine (miscellaneous) and Pharmacology for 2023, highlights its significance and impact within the scientific community. Ranking #199 out of 636 in General Medicine and #217 out of 313 in Pharmacology on the Scopus scale, the journal aims to foster innovative discussions and developments among researchers, professionals, and students, making it an essential tool for those seeking to stay at the forefront of clinical research and trials.

Movement Disorders Clinical Practice, published by WILEY, is an essential peer-reviewed journal dedicated to advancing the understanding and treatment of movement disorders from a clinical perspective. With an ISSN of 2330-1619, this journal serves as a vital resource for researchers, clinicians, and students engaged in neurology and clinical neuroscience. Since its inception in 2014, the journal has established itself within the medical community, currently positioned in the Q2 category for both Neurology and Neurology (Clinical), reflecting its influence and reputation. Although it does not offer open access, the journal is integral for disseminating high-quality research and clinical insights, thereby contributing significantly to improved patient care and outcomes in the field of movement disorders. Based in Hoboken, NJ, it continues to attract contributions from leading experts and aims to foster a deeper understanding and dialogue surrounding contemporary challenges and advancements in movement disorder treatment.

Nature Reviews Drug Discovery, published by Nature Portfolio, is a premier academic journal dedicated to the field of drug discovery. Since its inception in 2002, this journal has become an essential resource for researchers, professionals, and students, providing high-quality, peer-reviewed articles that present the latest advancements and insights into the complex landscape of pharmaceutical development. With an impressive impact factor placing it in the Q1 category across multiple disciplines, including Drug Discovery and Pharmacology, it continues to lead the way in pharmacological research, evidenced by its top ranks in Scopus among peers. Although it is not an open-access publication, the journal remains a vital tool for those looking to stay abreast of emerging trends and innovations in drug research. For more details about their submission guidelines and access options, visit the official journal website.

ANNALS OF NEUROLOGY, published by Wiley, stands as a leading journal in the field of neurology, renowned for its rigorous peer-reviewed articles that contribute significantly to the understanding of neurological disorders and advances in clinical practices. With an impressive impact factor and ranked Q1 in both neurology and clinical neurology categories, this journal positions itself among the top repositories of cutting-edge research, indexed in Scopus with exemplary ranks in the 98th and 97th percentiles respectively. Since its inception in 1977 and with a commitment to excellence extending to 2024 and beyond, ANNALS OF NEUROLOGY aims to disseminate groundbreaking studies and foster dialogue within the academic community, making it an essential resource for researchers, healthcare professionals, and students dedicated to neurology. Although it does not currently offer open access, its accessibility through institutional subscriptions facilitates widespread scholarly engagement.

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

Neurology Research International, published by HINDAWI LTD, is an esteemed open access journal that has been serving the neurology community since 2010. With its ISSN 2090-1852 and E-ISSN 2090-1860, this journal aims to foster knowledge dissemination and facilitate dialogue surrounding key issues in neurology and clinical neuroscience, making it a vital resource for researchers, clinicians, and students alike. It operates from the United States, with its administrative hub located in London, England. As of 2023, the journal has been positioned in the Q3 category for both neurology and clinical neurology, reflecting its commitment to advancing research within these critical fields. With a current Scopus rank of #216/400 in clinical neurology and a #113/192 in neuroscience, and a converged publication timeline from 2010 to 2024, Neurology Research International is dedicated to promoting high-quality research that addresses contemporary challenges and innovations in neurological science. By offering open access since its inception, it ensures that cutting-edge research is freely available, aligning with the global push towards accessible scientific communication.